Filgrastim Biosimilars Market Report 2026

The filgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.19 billion in 2025 to $1.33 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to high cost of originator filgrastim, increasing prevalence of cancer and blood disorders, limited access to biologics in emerging regions, growing hospital infrastructure, early approvals of biosimilars by regulatory authorities.

The filgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to launch of next-generation filgrastim biosimilars, expansion of contract manufacturing partnerships, increasing adoption in chronic and autoimmune diseases, rising government support and reimbursement policies, development of patient-centric distribution and delivery models. Major trends in the forecast period include rising adoption of filgrastim biosimilars in oncology and blood disorder treatments, expansion of contract manufacturing organizations for biosimilar production, increasing use of in-house vertically integrated manufacturing facilities, growing preference for hospital and retail pharmacy distribution channels, focus on cost-effective biologics and access in emerging markets.

The climbing cancer incidence is set to fuel expansion in the filgrastim biosimilars market ahead. Cancer involves disorders where abnormal cells proliferate wildly and metastasize, triggered by genetic changes derailing cell control. This upsurge partly stems from aging populations, as extended lifespans heighten mutation risks leading to malignancy. Filgrastim biosimilars aid cancer patients by stimulating white blood cell formation, curbing chemotherapy-linked neutropenia risks, and supporting safer, uninterrupted therapy. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, logged 354,820 new cancer diagnoses in 2023 - averaging 972 daily, up 8,605 from 2022. Therefore, the rising cancer incidence is driving the filgrastim biosimilars market.

Prominent companies in the filgrastim biosimilar market are advancing novel offerings via cutting-edge methods like recombinant DNA technology for biosimilar production. Recombinant DNA technology crafts hybrid DNA by grafting foreign sequences into host organisms. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, debuted FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA, in the United States for treating and preventing febrile neutropenia. It fosters neutrophil growth and differentiation from precursors, spurs maturation, and boosts mature cell function and survival, yielding dose-tied neutrophil elevations. The FYLNETRA rollout bolsters affordable drug access for patients, providers, and payers.

In August 2025, Intas Pharmaceuticals Ltd., an India-based pharmaceutical company, partnered with Accord Healthcare Inc. to purchase the Udenyca business from Coherus Biosciences, Inc. for an undisclosed amount. Through this partnership, Intas Pharmaceuticals and Accord Healthcare seek to rank among top global pegfilgrastim suppliers by merging Intas’ and Accord’s sales and logistics strengths with Coherus’ proven lineup, widening patient reach, sustaining momentum, and securing steady supply in the US and worldwide markets. Coherus Biosciences Inc. is a US-based biotechnology company that specializes in the development, manufacture, and commercialization of biosimilar therapies for oncology and autoimmune indications.

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the filgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the filgrastim biosimilars market by raising costs of imported active pharmaceutical ingredients (APIs), biologics, and fill-and-finish services, affecting production timelines and pricing. Hospital and retail pharmacy distribution channels in North America and Europe are most affected due to their reliance on imported biosimilars. While tariffs have increased operational costs, they have also encouraged local manufacturing, investment in domestic production facilities, and innovation in biosimilar manufacturing to improve supply security and cost efficiency.

The filgrastim biosimilars market research report is one of a series of new reports that provides filgrastim biosimilars market statistics, including filgrastim biosimilars industry global market size, regional shares, competitors with a filgrastim biosimilars market share, detailed filgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the filgrastim biosimilars industry. This filgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Filgrastim biosimilars are biosimilar drugs designed to treat patients with bone marrow damage from high radiation exposure, functioning similarly to their use in cancer care by stimulating white blood cell production and reducing susceptibility to infections.

The main types of manufacturing in the filgrastim biosimilar market are in-house manufacturing and contract manufacturing organizations (CMOs). CMOs, also called contract development and manufacturing organizations, provide end-to-end services to pharmaceutical companies on a contractual basis, covering processes from drug discovery to production. These biosimilars are applied in oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and more, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The filgrastim biosimilar markets consist of sales of Zarxio, Nivestym, and Releuko. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.